Table 3.
Availability of therapy options for multiple sclerosis in 20 Latin American countries in 2011 [63]
| Availability | n (%) |
|---|---|
| Acute crisis | |
| Methylprednisolone | 20 (100) |
| Intravenous gamma globulin | 20 (100) |
| Plasmapheresis | 18 (90) |
| Immunomodulators | |
| Interferons | 20 (100) |
| Glatiramer acetate | 7 (35) |
| Biosimilars | 7 (35) |
| Natalizumab | 11 (55) |
| Fingolimod | 4 (20) |
| Immunosuppressive drugs | |
| Azathioprine | 20 (100) |
| Cyclophosphamide | 20 (100) |
| Mitoxantrone | 18 (90) |
| Participation in associations/studies/guides | |
| Patient-family associations | 20 (100) |
| MS centers/clinics | 12 (60) |
| National clinical studies | 11 (55) |
| International clinical studies | 12 (60) |
| MS academic associations | 10 (50) |
| Clinical trials | 10 (50) |
| Treatment guides | 10 (50) |
| Therapeutic effectiveness trials | 2 (10) |
North America Mexico, Cuba, Puerto Rico, Dominican Republic; Central America Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama; South America Argentina, Bolivia, Brazil, Colombia, Chile, Ecuador, Paraguay, Peru, Uruguay, Venezuela
MS multiple sclerosis